Background/Aims: Type 2 Diabetes Mellitus (T2DM) is characterized by insulin resistance (IR), but the underlying molecular mechanisms are incompletely understood. MicroRNAs (miRNAs) have been demonstrated to participate in the signalling pathways relevant to glucose metabolism in IR. The purpose of this study was to test whether the multiple-target antimiRNA antisense oligonucleotides (MTg-AMO) technology, an innovative miRNA knockdown strategy, can be used to interfere with multiple miRNAs that play critical roles in regulating IR. Methods: miR-30d was constructed (MTg-AMO 106b/27a/30d ). Protein levels were determined by Western blot Insulin resistance was analysed with glucose consumption and glucose uptake assays. Results: We found that the protein level of glucose transporter 4 (GLUT4), Mitogen-activated protein kinase 14 (MAPK 14), Phosphatidylinositol 3-kinase regulatory subunit beta (PI3K regulatory subunit beta) and mRNA level of Slc2a4 (encode GLUT4), Mapk14 (encode MAPK 14) and Pik3r2 (encode PI3K rats and in insulin-resistant L6 cells. Overexpression of miR-106b, miR-27a and miR-30d in L6 cells decreased glucose consumption and glucose uptake, and reduced the expression of GLUT4, MAPK 14 and PI3K regulatory subunit beta. Conversely, silencing of endogenous miR-106b, miR-27a and miR-30d in insulin-resistant L6 cells enhanced glucose consumption and glucose uptake, and increased the expression of GLUT4, MAPK 14 and PI3K regulatory subunit beta. MTg-AMO 106b/27a/30d up-regulated the protein levels of GLUT4, MAPK 14 and PI3K regulatory subunit beta, enhanced glucose consumption and glucose uptake. Conclusion: Our data suggested that miR-106b, miR-27a and miR-30d play crucial roles in the regulation of glucose metabolism by targeting the GLUT4 signalling pathway in L6 cells. Moreover, MTg-AMO 106b/27a/30d offers more potent effects than regular singular AMOs.
Regulation of Insulin Resistance by

Introduction
Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder that is characterized by hyperglycaemia and it accounts for approximately 90% of all cases of diabetes [1] [2] [3] . Insulin resistance is a prominent feature central to the development of T2DM, which decreases the ability of insulin to interact with insulin-sensitive tissues (especially muscle, liver, and fat), impairs glucose utilization, and induces hepatic glucose output [4, 5] . Although many genetic and physiological factors contribute to insulin resistance, the precise molecular mechanisms have not been elucidated. Glucose transporter 4, also known as GLUT4, is an insulinregulated glucose transporter found primarily in adipose, skeletal or cardiac tissues [6] [7] [8] [9] . Insulin induces translocation of GLUT4 from intracellular vesicles to the plasma membrane, which permits the facilitated diffusion of circulating glucose down its concentration gradient into muscle cells leading to a rapid increase in the uptake of glucose. Accumulating evidence indicates that either expression deregulation or functional impairment of GLUT4 can cause insulin resistance. Because of its crucial role, GLUT4 has been considered to be a potential therapeutic target for T2DM.
MicroRNAs (miRNAs), a class of endogenous non-coding RNAs of approximately 22 nucleotides in length, play primary regulatory roles in animals and plants by binding to translation [10] [11] [12] [13] . Numerous studies have demonstrated that miRNAs are involved in many biological processes, such as cell development, differentiation, apoptosis and proliferation [14, 15] . Notably, miRNAs have been documented to regulate insulin synthesis, secretion and insulin resistance [21] [22] [23] . For example, overexpression of miR-29 leads to insulin resistance in 3T3-L1 adipocytes [24] ; miR-320 augments insulin sensitivity during insulin resistance by regulating the insulin-IGF-1 signalling pathways [25] ; miR-30d negatively regulates the expression of the insulin gene [17] ; miR-133 regulates the expression of GLUT4 by targeting KLF15 in cardiomyocytes [26] ; and miR-223 regulates GLUT4 expression and myocardial glucose metabolism [27] . Our pilot studies indicate that a number of miRNAs such as miR106b, miR-27a and miR-30d, in addition to miR-133 and miR-223, have the potential to target the GLUT4 gene and contribute to insulin resistance. us to hypothesize that insulin resistance is controlled by multiple miRNAs, through multiple signalling pathways or through a single gene as a common target of multiple already documented by published studies, and of miR-106b, miR-27a and miR-30d, as well that remained yet to be examined. On the other hand, in considering utilizing miRNAs as therapeutic targets for GLUT4-associated insulin resistance, it remains unclear what is the GLUT4-regulating miRNA or targeting GLUT4 regulator miRNAs. One of the indispensable approaches in miRNA research is knockdown of miRNAs by anti-miRNA oligonucleotides (AMOs). Through irreversible binding to target miRNAs, AMOs allow for effective lossof-function of miRNAs and consequent gain-of-function of their target genes. To achieve concomitant knockdown of multiple miRNAs, co-application of multiple singular AMOs has been used. However this strategy, while effective in some cases, may be problematic in , if not impossible. To tackle this problem, our group has developed an innovative strategy: multiple-target antisense units that are engineered into a single oligonucleotides fragment to acquire the capacity of simultaneously silencing multiple-target miRNAs. Studies suggest that MTg-AMO is an improved approach for miRNA target gene discovery and for studying the functions of miRNAs. The aims of this study were two folds 106b, miR-27a and miR-30d in regulating GLUT4 and their associated signalling pathways thereby their roles in insulin resistance; and second, in knocking down these miRNAs as compared with that of the regular AMOs. Our results support the view that insulin resistance is controlled by multiple miRNAs and simultaneous caused by these miRNAs. Animals and establishment of diabetic model M of Harbin Medical University, China. Animals were maintained at 24°C for one week and subjected to a 12 h:12 h light-dark cycle with a constant humidity of 55±5%. The rats were divided randomly into two groups: the control group and the Type 2 Diabetes Mellitus (T2DM) group. According to previous studies [29] [30] [31] , the rats were intragastrically administered with a fat emulsion (10 ml/d) prepared with 20 g lard, 5 g cholesterol, 1 g thyreostat, 5 g sucrose, 1 g sodium glutamate, 5 g saccharum, 20 ml tween-80, and 30 ml of 100 ml distilled water for 15 d. Then, the animals were subjected to intraperitoneal injection of 30 mg/kg/d streptozocin (STZ) in a 0.1 M citrate buffer solution (pH4.2) for 3 d. Animals were fasted for 12 h before sampling. Blood samples were collected and fasting blood glucose (FBG) level was detected at 72 h after the last injection of STZ to ensure that T2DM had been successfully established (glycaemia > 16.7 mmol/L). 
Materials and Methods
Ethics statement
Cell transfection
The miR-106b, miR-30d and miR-27a mimics, AMO-106b, AMO-27a, AMO-30d, and a negative control (NC) were synthesized by Guangzhou Ribo Bio Co., Ltd., China. The multiple-target AMO (MTg-AMO) was synthesized by EXIQON, USA. The MTg-AMO tested in this study was designed to integrate the AMOs against miR-106b, miR-27a and miR-30d into one AMO (MTg-AMO 106b/27a/30d ). The sequences of the anti-miRNA antisense inhibitors (AMOs), the multiple-target AMO (MTg-AMO), the mutant sequences of the AMOs and MTg-AMO 106b/27a/30d are listed as following: AMO-106b (5 -ATC TGC ACT GTC AGC ACT TTA-3 ), Mutant AMO-
The constructs were added to L6 cells after they had been starved for 24 h in serum-free medium using the X-treme GENE siRNA transfection reagent (catalog#: 04476093001; Roche, USA), according to the manufacturer's instructions. Protein and RNA samples were extracted for analysis 24 h after transfection.
RNA isolation and quantitative real-time RT-PCR (qRT-PCR)
Total RNA samples were extracted from rat skeletal muscle tissue and L6 cells with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The cDNA was obtained by the Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. The SYBR Green PCR Master RNAs. Real-time PCR was performed with the 7500 Fast Real-Time PCR System (Applied Biosystems) to determine the relative levels of miR-106b, miR-27a, miR-30d, Slc2a4, Mapk14 and Pik3r2. The sequences of the primers used in this study are shown as following: Slc2a4 Mapk14 (Forward: 5 -UGU CCA UCC CAC UUC ACU GUGAG-3 ; Reward: 5 -CGC CUU GAA UCG GUG ACA CUU-3 ); Pik3r2 (Forward: 5 -CCG CUG CGU CUG CCA UGU UUACA-3 5 -GAA GGU CAG CCC CUA CAA AUGU-3 5 -AAG AAG GTG GTG AAG CAGGC-3 5 -TCC ACC ACC CAG TTG CTGTA-3 cycles with GAPDH and U6 used as internal controls.
Protein extraction and Western blot analysis
The protein samples were extracted from L6 cells and rat skeletal muscle tissue. Total protein was fractionated by SDS-PAGE (12% polyacrylamide gels) and transferred to nitrocellulose (NC) membranes. The membranes were blocked with Western blocking buffer for 2 h and then incubated at 4°C overnight. The following primary antibodies were used: GLUT4 (Abcam, USA), MAPK 14 (Cell Signaling Technology, Danvers, MA, USA), PI3K regulatory subunit beta (Cell Signaling Technology, Danvers, MA, USA) and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA). Images were detected using the Odyssey infrared measuring the band intensity (Area×OD) for each group and the values were all normalized to GAPDH as an internal control.
by incubation with lipofectamine 2000 containing miR-106b mimic, AMO-106b, miR-30d mimic, AMO-30d, miR-27a mimic, AMO-27a, MTg-AMO 106b/27a/30d paraformaldehyde for 30 min at room temperature, permeabilized with 0.1% Triton X-100 for 1 h, and blocked with goat serum for 2 h. GLUT4, MAPK 14 and PI3K regulatory subunit beta were incubated with their respective primary antibodies for 24 h and then with the conjugated secondary antibody for 1 h. The nuclei were visualized with DAPI (4', 6-diamidino-2-phenylindole) at room temperature for 30 min, and with insulin (100 nmol/L) for 30 min, and then incubated for 10 min in glucose free medium containing 2-deoxyglucose. The amount of 2-NBDG taken up by cells was measured at the wavelengths designed to
Luciferase assays -UTRs of -UTR were synthesized by Sangon -UTR luciferase vector was co-transfected with miRNA mimics or AMOs into human embryonic kidney 293 (HEK293) cells using Lipofectamine 2000 (Invitrogen), with Renilla luciferase reporters used as an internal control. Luciferase activity assay was performed 48 h following transfection using the Dual-Luciferase Reporter Assay System (Promega Biotech Co., Ltd.) according to the manufacturer's protocol.
Data analysis
Data are expressed as mean ± S.E.M. Statistical comparisons were performed by t-test between two were analysed using the GraphPad Prism 5.0.
Results
To explore the role of the GLUT4 signalling pathway in our rat model of T2DM and in GLUT4, MAPK 14, and PI3K regulatory subunit beta expression at the protein level. As shown in Fig. 1A & B, GLUT4, MAPK 14, and PI3K regulatory subunit beta diabetic group compared to the control group. We then measured the changes in miRNAs known to be associated with the skeletal muscle tissue of diabetic rats, including miR-17, miR-20, miR-24, miR-27a, miR-30d, miR-93, miR-106b and miR-520 [33] [34] [35] . Compared the diabetic group (data not shown). Using TargetScan miRNA database for target gene -UTRs of Slc2a4 (encoding GLUT4), Mapk14 (encoding MAPK 14), and Pik3r2 (encoding PI3K regulatory subunit beta) genes carry the binding sites for miR-106b, miR-27a, and miR-30d, respectively. resistance, we established the relationship between miR-106b and GLUT4 using both gain-and loss-of-function approaches. As shown in Fig. 2A & B, miR-106b suppressed the -UTR of Slc2a4, whereas mutation of the binding sites attenuated the action of miR-106b. Consistently, overexpression of miR-106b GLUT4 (Fig. 2C & D) . Conversely, knockdown of miR-106b by AMO-106b increased GLUT4 protein levels in insulin-resistant 2F & G). Strikingly, overexpression of miR-106b decreased the glucose consumption and uptake levels in L6 cells (Fig. 2H) , and knockdown of miR-106b by AMO-106b increased them in IR L6 cells (Fig. 2I) . Comparisons between the IR L6 cells (IR) and non-treated L6 decreased in the former (Fig. 2I) , indicating the development of IR after insulin treatment in L6 cells.
We next investigated the link between miR-27a and MAPK 14 that carries two -UTR (Fig. 3A) . Our luciferase reporter gene assay clearly demonstrated that miR-27a suppressed the luciferase activity of the vector carrying the Mapk14 -UTR, whereas mutation of the binding sites relieved the repressive action of miR27a (Fig. 3B ). Furthermore, the protein level of MAPK 14 overexpression of miR-27a in IR L6 cells (Fig. 3C & D) ; conversely, it was remarkably upregulated by AMO-27a to knockdown endogenous miR-27a (Fig. 3E) . These results were overexpression mitigated the glucose consumption and uptake in L6 cells, but its knockdown facilitated these processes in IR L6 cells (Fig. 3H & I) .
We further determined the link between miR-30d and PI3K regulatory subunit beta using the same approach as described for miR-106b and miR-27a. As shown in Fig. 4A, Pik3r2 -UTR. Transfection of miR-30d -UTR of Pik3r2, and this action was abrogated by the vector carrying the mutant binding sites (Fig. 4B ). As depicted in Fig. 4C & D, transfection of miR-30d into L6 cells remarkably reduced the protein level of PI3K regulatory subunit beta. In contrast, PI3K regulatory subunit beta regulated in IR L6 cells transfected with AMO-30d (Fig. 4E) . Immunostaining revealed that miR-30d overexpression markedly diminished PI3K regulatory subunit beta density and this effect was rescued by AMO-30d (Fig. 4F & G) . In addition, the glucose consumption level and glucose uptake were inhibited by miR-30d overexpression but improved by AMO-30d in IR L6 cells (Fig. 4H & I) . 
expression in L6 cells
The results presented above clearly indicate that multiple miRNAs (miR-106b, miR-27a and miR-30d) are involved in the regulation of the GLUT4/MAPK 14/PI3K regulatory subunit beta signalling pathway. Together with our data showing the substantial upregulation of all these three miRNAs in T2DM and IR cells, we contemplated that it might be highly desirable to simultaneously knockdown these miRNAs in order to achieve a better outcome in correcting 106b/27a/30d to knockdown endogenous miR-106b, miR-27a and miR-30d all at once. As shown in Fig. 5A , the levels of miR-27a, miR-30d and miR-106b were reduced by 99.7%, 99.1%, and 58.7%, respectively, upon transfection of the MTg-AMO 106b/27a/30d . We then went on to investigate the ability of the MTg-AMO 106b/27a/30d to relieve the tonic repressive effects of the three miRNAs on their respective target genes. As depicted Fig. 5B & C, MTg-AMO 106b/27a/30d markedly increased the expression of MAPK 14, PI3K regulatory subunit beta and GLUT4 at both the mRNA and The ability of MTg-AMO 106b/27a/30d to up-regulate the expression of GLUT4 predicts its ability to regulate glucose metabolism. This was indeed evidenced by the data shown in Fig.  6A & B, the glucose consumption level and glucose uptake in L6 cells were both improved by MTg-AMO 106b/27a/30d treatment. In addition, MTg-AMO 106b/27a/30d increased GLUT4 intensity and GLUT4 translocation from the cytoplasmic membrane to the cytoplasm as 106b/27a/30d expression in insulin-treated L6 cells We then examined the effects of MTg-AMO 106b/27a/30d on GLUT4, MAPK 14 and PI3K regulatory subunit beta expression in insulin-treated L6 cells. As depicted in Fig. 7A , MTg-AMO 106b/27a/30d markedly decreased the levels of miR-27a, miR-30d and miR-106b in insulin-treated L6 cells. In addition, the protein and mRNA levels of MAPK 14, PI3K regulatory subunit beta and GLUT4, the respective target genes of the three miRNAs, were conversely increased by MTg-AMO 106b/27a/30d (Fig. 7B & C) . Similar results were obtained by 106b/27a/30d -treated L6 cells As shown in Fig. 8A & B, the glucose consumption level and glucose uptake were both markedly elevated by treatment with MTg-AMO 106b/27a/30d in insulin-treated L6 cells. In addition, MTg-AMO 106b/27a/30d decreased GLUT4 expression and GLUT4 translocation (Fig.  8C) .
Discussion
In the present study, we aimed to identify the miRNA regulators of the GLUT4 signalling pathway and their roles in governing glucose metabolism, and to assess the effectiveness and pathophysiological functions of miRNAs. Our experiments provided the following main and in insulin-resistant L6 cells. Second, the upregulation of these miRNAs diminished GLUT4 signalling by repressing the expression of GLUT4, MAPK 14 and PI3K regulatory subunit beta, respectively. Third, the impairment of the GLUT4 signalling pathway due, at least partially, to the upregulation of miR-106b, miR-27a and miR-30d resulted in considerable weakening of the glucose metabolism. Finally, normalization of endogenous levels of these three miRNAs by their respective antisense inhibitor AMOs effectively corrected the impaired GLUT4 signal transduction and restored the damaged glucose metabolism to normal levels. Notably, the allow us to conclude: (1) miR-106b, miR-27a and miR-30d critically regulate the main components (GLUT4, MAPK 14 and PI3K regulatory subunit beta) of the GLUT4 signalling disorder thereby insulin resistance; and (3) the MTg-AMO approach is a superior strategy for concomitant normalization of deregulated miRNAs and subsequent glucose metabolism. Insulin resistance is an independent causal factor for diabetes mellitus [3, 9] . Defect in caused by impairment of a wide spectrum of cellular processes including glucose delivery, transport, and phosphorylation [26, 36] . Yet, the precise mechanisms for insulin resistance are complex and remain incompletely understood [37, 38] . Among the various factors, GLUT4 is known to mediate the peripheral tissue insulin stimulation of glucose uptake in many tissues, particularly in skeletal muscle, because they help control glucose metabolism in muscular tissues [5, 39, 40] . Recent reports demonstrated that MAPK 14 is highly expressed and activated in human omental (OM) adipose tissue in obesity [41] and in liver [42, 43] . Activation of MAPK 14 in liver is critically involved in the ROS-induced impairment of insulin signalling and in stress-induced IRS-1 serine phosphorylation as well, promoting hepatic insulin resistance [39] . MAPK 14 has been shown to increase GLUT4 expression and lipid accumulation in differentiated 3T3-L1 adipocytes [44] . Class IA phosphatidylinositol 
46].
While these aforementioned studies support the critical involvement of GLUT4, MAPK 14 and PI3K regulatory subunit beta in regulating glucose metabolism with their expression deregulation and functional impairment favouring insulin resistance, these genes are under the delicate regulation by miRNAs. For instance, overexpression of let-7 can result in insulin resistance and impaired glucose tolerance [38, 47] ; in contrast, knockdown of the let-7 family miRNAs reverses impaired glucose tolerance, presumably by improving insulin sensitivity in the liver and muscles [39, 48] . Previous studies showed that in insulin-responsive tissues such as skeletal muscles, PI3K can induce phosphorylation of Akt that directly mediates [49] . Insulin results in p38-induced GLUT4 activation in muscles and fat cells, and MAPK 14 can induce GLUT4 activation at the plasma membrane even in the absence of insulin treatment [50] . Our bioinformatics analysis and in vitro study revealed that miR-27a, miR-106b and miR-30d could regulate MAPK 14, GLUT4 and PI3K regulatory subunit beta, respectively, in L6 cells, which suggests that all three miRNAs contribute to the cellular functions relevant to the insulin signaling pathway in rat.
with individuals with normal glucose tolerance [33] . MiR-106b is associated with skeletal muscle insulin resistance and T2DM [34] . The expression of miR-27a was found increase in adipose tissue of a spontaneous T2DM rat model [35] . MAPK 14 or PI3K regulatory subunit beta locates upstream of GLUT4 in the signaling pathway; this conclusion stems from both published studies and the results generated in the present study. Previous studies have shown that in insulin-responsive tissues such as skeletal muscle, PI3K can induce phosphorylation by insulin regulates GLUT4 activity [33] , and MAPK 14 -mediated activation of GLUT4 occurs at the plasma membrane. These results suggest that both of the PI3K-Akt MAPK 14 signaling found that miR-27a, miR-106b and miR-30d regulated MAPK 14, GLUT4 and PI3K regulatory subunit beta, respectively, in L6 cells, suggesting that all three miRNAs contribute to GLUT4 signaling.
Here, we found that miR-106b/27a/30d expression was increased in diabetic skeletal muscle and GLUT4/MAPK 14/PI3K regulatory subunit beta as the target genes of these three miRNAs were reciprocally down-regulated. The down-regulation of GLUT4/MAPK 14/PI3K regulatory subunit beta eventually resulted in glucose metabolism disorders. These adverse changes were reversible: normalization or knockdown of miR-106b/27a/30d levels by their GLUT4/MAPK 14/PI3K regulatory subunit beta pathway in connection to the glucose metabolism is regulated by multiple miRNAs. In related miRNAs is highly desirable. In respect with this notion, we examined the effects of multiple-target AMO strategy that allows for concurrent inhibition of pre-determined multiple miRNAs by a single AMO fragment. The theory of MTg-AMO has been examined in a previous study [28] ; miR-21, miR-155 and miR-17 promote tumour genesis and the antisense inhibitors of these three miRNAs are integrated into a single fragment. The result showed that the effect of MTg-AMO 21/155/17-5p is stronger than the combined use of the same dose of a single miRNA antisense nucleotide (AMO-21, AMO-155 and AMO-17). In this study, we tested the effect of MTg-AMO 106b/27a/30d on glucose metabolism using the MTg-AMO approach, and found that MTg-AMO 106b/27a/30d AMOs. However, more rigorous studies are warranted to optimize the desired effectiveness of MTg-AMO 106b/27a/30d .
